英为财情Investing.com - ProPhase Labs (NASDAQ: PRPH )星期一发布了第一季度的财报，数据显示，公司营收高于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-1.860，总营收为$18.95M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$5.88M，每股收益为$-0.240.

Investing.com — ProPhase Labs Inc.公布的2024年第四季度业绩大幅低于预期，每股收益 (EPS)为-$1.86，而预期为-$0.24。公司收入达到$18.95百万，超过预期的$5.88百万。尽管收入超预期，但该公司股价在盘前交易中下跌8.18%，反映了投资者对业绩不佳和未来盈利能力的担忧。

ProPhase Labs Inc (PRPH) outlines cost-cutting measures and potential liquidity events amid financial constraints and stock price concerns.

Analysts anticipate ProPhase Labs to report an earnings per share (EPS) of $-0.24. The market awaits ProPhase Labs's ...

Q4 2024 Earnings Call Transcript March 31, 2025 ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $-1.86 ...

On behalf of our team, we want to thank everyone for joining us today for ProPhase Labs Fourth Quarter and Year-End 2024 Results. ProPhase is trading on the NASDAQ under the ticker symbol PRPH.

ProPhase Labs, Inc., a company specializing in pharmaceutical preparations with a current market capitalization of $8.16 million, has announced an executive shift with the departure of its current ...

Net revenue for the year ended December 31, 2024, decreased $28.2 million, or 80.6%, to $6.8 million compared to $35.0 million for the year ...

Mitosis is conventionally divided into five stages known as prophase, prometaphase, metaphase, anaphase, and telophase. While mitosis is taking place, there is no cell growth and all of the ...

GARDEN CITY, NY, March 31, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and ...

Find the latest ProPhase Labs, Inc. PRPH analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.